VBLT News and Press, Vascular Biogenics Ltd. From 05/04/21

TEL AVIV, Israel, May 04, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its first quarter financial results for the period ended March 31, 2021 on Tuesday, May 11, 2021 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financ...

TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced the closing of its underwritten public offering of 6,901,790 ordinary shares, and, to certain investors in...

Vascular Biogenics (VBLT) prices public offering of 5.15M shares, to certain investors in lieu thereof pre-funded warrants to purchase 8.05M shares, at $1.90 per share and $1.89 per pre-funded warrant.Underwriters' overallotment option is to purchase up to additional 15% of offering.Gros...

TEL AVIV, Israel, April 09, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced the pricing of an underwritten public offering of 5,150,265 ordinary shares and, to certain investors in lieu thereo...

Vascular Biogenics (VBLT) announces that it intends to offer and sell ordinary shares and pre-funded warrants to purchase shares in an underwritten public offering.Expects to grant the underwriters a 30-day option to purchase up to an additional 15% of aggregate number of shares plus the...

TEL AVIV, Israel, April 08, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced that it intends to offer and sell ordinary shares and, to certain investors in lieu thereof, pre-funded warrants to ...

TEL AVIV, Israel, March 30, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it will host a virtual R&D Day for analysts and investors beginning at 10:00am ET on Tuesday, April 6, 2021. The event will include presentations from Professor Dror Harats, M.D, Ch...

Vascular Biogenics Ltd. (VBLT) Q4 2020 Earnings Conference Call March 25, 2021, 08:30 AM ET Company Participants Lee Roth - IR Dror Harats - CEO Amos Ron - CFO Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Jonathan Aschoff - ROTH Capital Partners Jonathan Kreizman - Va...

VBL Therapeutics (VBLT): FY GAAP EPS of -$0.55 misses by $0.02.Revenue of $0.92M (+64.3% Y/Y) misses by $0.02M.Press Release For further details see: VBL Therapeutics EPS misses by $0.02, misses on revenue

Conference Call and Webcast at 8:30 a . m . EDT Today Continued progress in OVAL Phase 3 registration enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer; high CA-125 response rates (RR)...